MX2020008053A - Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat). - Google Patents

Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat).

Info

Publication number
MX2020008053A
MX2020008053A MX2020008053A MX2020008053A MX2020008053A MX 2020008053 A MX2020008053 A MX 2020008053A MX 2020008053 A MX2020008053 A MX 2020008053A MX 2020008053 A MX2020008053 A MX 2020008053A MX 2020008053 A MX2020008053 A MX 2020008053A
Authority
MX
Mexico
Prior art keywords
pyridin
methyl
ghrelin
goat
substitute
Prior art date
Application number
MX2020008053A
Other languages
English (en)
Inventor
Christoph Hoenke
Thomas Trieselmann
Viktor Vintonyak
Cédrickx Godbout
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2020008053A publication Critical patent/MX2020008053A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula general I, (Ver Fórmula), en donde los grupos R1 y R2 se definen de acuerdo con la reivindicación 1, que tienen propiedades farmacológicas valiosas, en particular, se fijan a ghrelin O-aciltransferasa (GOAT) y modulan su actividad. Los compuestos son adecuados para el tratamiento y la prevención de enfermedades que se pueden ver influenciadas por este receptor, tales como enfermedades metabólicas, en particular, obesidad.
MX2020008053A 2018-02-02 2019-01-28 Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat). MX2020008053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18154824 2018-02-02
PCT/EP2019/051989 WO2019149657A1 (en) 2018-02-02 2019-01-28 Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors

Publications (1)

Publication Number Publication Date
MX2020008053A true MX2020008053A (es) 2020-09-07

Family

ID=61157050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008053A MX2020008053A (es) 2018-02-02 2019-01-28 Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat).

Country Status (21)

Country Link
US (1) US11254688B2 (es)
EP (1) EP3746451B1 (es)
JP (1) JP7015396B2 (es)
KR (1) KR20200116978A (es)
CN (1) CN111655700B (es)
AU (1) AU2019215707A1 (es)
BR (1) BR112020013082A2 (es)
CA (1) CA3087826A1 (es)
CL (1) CL2020001907A1 (es)
CO (1) CO2020009299A2 (es)
CR (1) CR20200332A (es)
EA (1) EA202091805A1 (es)
EC (1) ECSP20050785A (es)
IL (1) IL276136A (es)
JO (1) JOP20200190A1 (es)
MA (1) MA53075A (es)
MX (1) MX2020008053A (es)
PE (1) PE20210174A1 (es)
PH (1) PH12020551168A1 (es)
SG (1) SG11202006125VA (es)
WO (1) WO2019149657A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054928T2 (hu) 2016-08-05 2021-10-28 Boehringer Ingelheim Int Oxadiazolopiridin-származékok ghrelin O-aciltranszferáz (GOAT)-inhibitorokként törtenõ alkalmazásra
WO2019149658A1 (en) * 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
CR20200332A (es) 2018-02-02 2020-09-03 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)
JP2023526351A (ja) 2020-05-22 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの製造方法
EP4153600A1 (en) 2020-05-22 2023-03-29 Boehringer Ingelheim International GmbH Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
WO2023114472A1 (en) * 2021-12-16 2023-06-22 Icahn School Of Medicine At Mount Sinai Heterocyclic compounds as 5ht2a biased agonists
CN114426516B (zh) * 2022-02-16 2022-11-04 安徽有吉医药科技有限公司 一种2-氨基-3-溴吡啶的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082383A1 (en) 2003-03-17 2004-09-30 Basf Aktiengesellschaft Use of triazolopyrimidines for combating nematode diseases of plants
AU2007273057A1 (en) * 2006-07-12 2008-01-17 Merck Sharp & Dohme Corp. Substituted pyrazoles as ghrelin receptor antagonists
EP2111414B1 (en) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
EP3088397B1 (en) 2007-04-11 2019-04-10 Canbas Co. Ltd. Compounds that abrogate the cell cycle g2 checkpoint for use in the treatment of cancer
CA2687611A1 (en) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Novel sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
FR2933989B1 (fr) 2008-07-16 2013-03-08 Commissariat Energie Atomique Procede de purification de microorganismes presents dans des echantillons liquides
FR2933975B1 (fr) 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
BRPI0823379A2 (pt) 2008-12-15 2015-07-14 Zealand Pharma As Análogos de glucagon
EA020596B1 (ru) 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
US20110078154A1 (en) 2009-09-28 2011-03-31 Accenture Global Services Gmbh Recruitment screening tool
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
CN104144696A (zh) 2011-12-23 2014-11-12 西兰制药公司 胰高血糖素类似物
WO2013125732A1 (en) * 2012-02-24 2013-08-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013192388A1 (en) * 2012-06-20 2013-12-27 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA118034C2 (uk) 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
US20170275249A1 (en) * 2014-09-17 2017-09-28 The Regents Of The University Of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
JP6615896B2 (ja) 2015-01-30 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロン合成酵素阻害剤
AR104673A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104672A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
JP6957460B2 (ja) 2015-10-22 2021-11-02 カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． アンジェルマン症候群および関連する障害の処置方法
HUE054928T2 (hu) * 2016-08-05 2021-10-28 Boehringer Ingelheim Int Oxadiazolopiridin-származékok ghrelin O-aciltranszferáz (GOAT)-inhibitorokként törtenõ alkalmazásra
NZ750126A (en) * 2016-08-11 2022-07-01 Cellix Bio Private Ltd Compositions and methods for the treatment of irritable bowel syndrome
WO2018044663A1 (en) 2016-08-29 2018-03-08 Merck Sharp & Dohme Corp. Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP3746450B1 (en) 2018-02-02 2022-03-16 Boehringer Ingelheim International GmbH Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CR20200332A (es) 2018-02-02 2020-09-03 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
WO2019149658A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors

Also Published As

Publication number Publication date
US11254688B2 (en) 2022-02-22
CL2020001907A1 (es) 2020-10-30
CR20200332A (es) 2020-09-03
CA3087826A1 (en) 2019-08-08
CN111655700A (zh) 2020-09-11
AU2019215707A1 (en) 2020-07-09
JP7015396B2 (ja) 2022-02-15
US20210053985A1 (en) 2021-02-25
CO2020009299A2 (es) 2020-08-21
MA53075A (fr) 2021-05-12
CN111655700B (zh) 2023-07-18
PH12020551168A1 (en) 2021-05-31
BR112020013082A2 (pt) 2020-12-01
EP3746451A1 (en) 2020-12-09
SG11202006125VA (en) 2020-07-29
IL276136A (en) 2020-09-30
EA202091805A1 (ru) 2020-12-16
ECSP20050785A (es) 2020-09-30
PE20210174A1 (es) 2021-01-29
JOP20200190A1 (ar) 2020-07-29
KR20200116978A (ko) 2020-10-13
WO2019149657A1 (en) 2019-08-08
EP3746451B1 (en) 2023-07-12
JP2021512113A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
MX2020008053A (es) Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat).
CR20200329A (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-acil transferasa (goat)
MX2020008116A (es) Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).
MY197064A (en) Oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
MX2020005873A (es) Compuestos de 6-azaindol.
MX2021005311A (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock).
MX2020006168A (es) Compuestos de 4-azaindol.
PH12017501925A1 (en) Pyrazole compounds and method for making and using the compounds
MX2020005462A (es) Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).
MX2020005515A (es) Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr).
MX2020006181A (es) Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5.
MX2015014944A (es) Derivados de 3-(2-aminopiridin-4-il)-5-(3-hidroxipropinil)-1h-pirr olo[2,3-c]piridina como inhibidores de la nik para el tratamiento del cancer.
MX2021005350A (es) Compuestos de piridazinona y usos de los mismos.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MX2011010918A (es) Metodo para el tratamiento de trastornos asociados con la actividad de la cinasa de proteina ck2.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
NO20090073L (no) 1,3-disubstitue 4-metyl-1H-pyrol-2-karboksamider og deres anvendelse for fremstlling av medikamenter
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2023011060A (es) Derivados de tetrahidrotieno piridina como inhibidores de los receptores del dominio de discoidina (ddr).
MX2023011058A (es) Derivados de tetrahidrotieno piridina como inhibidores de los receptores del dominio de discoidina (ddr).
MX2022005843A (es) Derivados de bencilamida como inhibidores del receptor i del factor de crecimiento transformante beta/ cinasa similar al receptor de activina 5 (alk5).
EA201991509A1 (ru) Аминозамещенные гетероциклические соединения в качестве ингибиторов ehmt2 и способы их применения